NCT04615949Phase 2, phase 3Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Study sponsor: Cardiol Therapeutics Inc. · CRDL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2022-11-30Actual
Enrollment · participants90Actual
Source updated2026-04-21Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: All-cause Mortality

+ After

Measure: Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular Complications

Check registry source